INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC

[Click here for information about joining the class action] On October 21, 2025, Alector issued a press release "announc[ing] results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)."Â The press release disclosed that latozinemab "did not meet the clinical co- primary endpoint of slowing FTD-GRNÂ progression," and that "the secondary and exploratory endpoints, such as fluid biomarkers and volume ...